Coherus BioSciences says it is “very pleased” with the progress of its Formycon-partnered Cimerli (ranibizumab-eqrn) biosimilar to Genentech’s Lucentis in the US, insisting that the company’s 190,000 doses shipped since launch and 30% volume share is “really important for ophthalmologists, because ophthalmologists have been burned time and again by novel agents that come on the market.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?